Covered recipient · General Payments record
MEGHAN C GADDIS
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2020–2022
$2,423.08
- Reported across 161 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2022 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $285.11 | 18 |
By paying entity
PY2022 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $84.09 | 5 |
| ABBVIE INC. | $83.97 | 5 |
| Novo Nordisk AS | $53.22 | 4 |
| Abbott Laboratories | $17.88 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.29 | 1 |
| JAZZ PHARMACEUTICALS INC. | $16.49 | 1 |
| Corcept Therapeutics | $12.17 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2022 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $17.88 | 01/25/2022 | Food and Beverage | Undisputed | 01/23/2026 | 920573139 | CMS |
| ABBVIE INC. | $16.40 | 01/24/2022 | Food and Beverage | Undisputed | 01/23/2026 | 890995031 | CMS |
| ABBVIE INC. | $13.62 | 01/25/2022 | Food and Beverage | Undisputed | 01/23/2026 | 890995033 | CMS |
| ABBVIE INC. | $19.97 | 02/10/2022 | Food and Beverage | Undisputed | 01/23/2026 | 890995035 | CMS |
| ABBVIE INC. | $13.02 | 02/21/2022 | Food and Beverage | Undisputed | 01/23/2026 | 890995037 | CMS |
| ABBVIE INC. | $20.96 | 07/28/2022 | Food and Beverage | Undisputed | 01/23/2026 | 890995039 | CMS |
| Amgen Inc. | $18.91 | 01/06/2022 | Food and Beverage | Undisputed | 01/23/2026 | 940063981 | CMS |
| Amgen Inc. | $11.38 | 02/03/2022 | Food and Beverage | Undisputed | 01/23/2026 | 939435927 | CMS |
| Amgen Inc. | $16.93 | 02/14/2022 | Food and Beverage | Undisputed | 01/23/2026 | 939435929 | CMS |
| Amgen Inc. | $17.26 | 03/08/2022 | Food and Beverage | Undisputed | 01/23/2026 | 939435931 | CMS |
| Amgen Inc. | $19.61 | 10/03/2022 | Food and Beverage | Undisputed | 01/23/2026 | 939435933 | CMS |
| Corcept Therapeutics | $12.17 | 02/16/2022 | Food and Beverage | Undisputed | 01/23/2026 | 948780979 | CMS |
| JAZZ PHARMACEUTICALS INC. | $16.49 | 02/15/2022 | Food and Beverage | Undisputed | 01/23/2026 | 951343479 | CMS |
| Novo Nordisk Inc | $12.77 | 01/04/2022 | Food and Beverage | Undisputed | 01/23/2026 | 899169655 | CMS |
| Novo Nordisk Inc | $13.06 | 01/10/2022 | Food and Beverage | Undisputed | 01/23/2026 | 898743377 | CMS |
| Novo Nordisk Inc | $13.28 | 01/19/2022 | Food and Beverage | Undisputed | 01/23/2026 | 899224287 | CMS |
| Novo Nordisk Inc | $14.11 | 02/25/2022 | Food and Beverage | Undisputed | 01/23/2026 | 899359387 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.29 | 02/01/2022 | Food and Beverage | Undisputed | 01/23/2026 | 955639535 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2021, 2022
- Source files
- Dataset page · Bulk file · PY2020 , PY2021 , PY2022
- Generated from
- OP_DTL_GNRL_PGYR2022_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.